Registries are a valuable source of disease expertise and patient data, recognized by FDA and EMA as important sources of evidence to inform decision making. Regulators, payers, and health technology assessment (HTA) bodies have explicitly delineated the key role for registry-based studies in their decision making.

Clinical registries offer unique data solutions including rich clinical data to provide differentiated insights to biopharma and biotech. Their contribution can span the product life cycle, from early clinical development (to optimize design and efficiently match the right patients to the right trials) to product launch (to inform submission dossiers and risk sharing agreements), to post-authorization safety and effectiveness studies. Registry-based studies are growing, in rare diseases where small numbers of patients are distributed across broad geographies, and because traditional electronic medical record (EMR) databases do not capture the clinical and patient outcomes found in registries. Collaboration with several registries simultaneously is often required to accrue enough data from patients with rare diseases or gather enough evidence about low frequency outcomes, and building on existing research networks of sites and patient populations creates a context for a more cost-effective study.

Given the strong connections with their stakeholder populations and their dedication to furthering research, registry groups are important partners in generating relevant real-world evidence to advance treatments.

This panel discussion focuses on:

  • Evolving and growing uses of registries in scientific research

  • Key factors in identifying the right study approach – Will existing registry data be sufficient? Is prospective data collection needed? Should a hybrid approach be used?

  • The importance of successful partnering with registries and their stakeholders

  • Use cases of registry-based studies – where they are most beneficial, use in post-marketing safety commitments, how to decide if they are right for your needs

  • Use of data science (e.g., natural language processing, machine learning) for data curation and analysis

  • Opportunities and challenges of coordinating multiple registries working on a scientific study

Javier Cid, MD, DrPH, MBA, MSc
Senior Research Scientist, Real-World Evidence, Data Analytics, Evidera, part of PPD
Javier Cid has experience planning, implementing, and analyzing several drug and disease registries and databases, as well as developing and implementing signal detection for pharmacovigilance. He has over 25 years’ experience, including 11 years in major pharmaceutical companies in the areas of pharmacoepidemiology and drug safety.
Nahila Justo, MPhil, MBA
Executive Director, Real-World Evidence, Integrated Solutions, Evidera, part of PPD
Nahila Justo has over 15 years of experience and is responsible for leading cross-functional teams focused on RWE generation and insights, especially the use and analysis of data sets such as clinical registries. She is active in advancing the adoption and implementation of RWE in health care decision-making through groups such as the GetReal Institute.
Delphine Saragoussi, MD, MScPH
Executive Director, Real-World Evidence, Strategic and Scientific Affairs, PPD, part of Thermo Fisher Scientific
Delphine Saragoussi, a physician in public health and social medicine, has 15+ years of experience in epidemiology and pharmacoepidemiology. She has a deep understanding of strategic real-world evidence (RWE) needs across the development life cycle and has developed and implemented various peri-/post-approval RWE plans to support successful market access.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country / Region*
Job Title*
Job Level*
Organization / Company*
Organization Type*
On a scale of 1-5, what is your familiarity/expertise with using clinical/disease registry data? *
1 - Not very familiar
5 - Very familiar
Are you considering a registry-based study in the next 12 months? *
Registration Terms
This event is hosted by HealthEconomics.Com (a Scientist.com company). By registering and participating, you acknowledge that your personal data will be processed by the webinar platform (BigMarker) and HealthEconomics.Com. You also agree to receive email communication from HealthEconomics.Com about this webinar and other programs of similar nature. The sponsor of this webinar is Evidera; by registering and participating, you acknowledge that your data will be processed in accordance with Evidera's Privacy Policy. You will receive email communication from Evidera about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Yes, I consent to the registration terms.*
Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.